News
AVCNF
0.173
+4.35%
0.007
Weekly Report: what happened at AVCNF last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at AVCNF last week (1201-1205)?
Weekly Report · 12/08 09:43
Weekly Report: what happened at AVCNF last week (1124-1128)?
Weekly Report · 12/01 09:41
Avicanna Inc. Reports Q3 2025 Earnings and Growth
TipRanks · 11/27 03:57
Weekly Report: what happened at AVCNF last week (1117-1121)?
Weekly Report · 11/24 09:44
Avicanna Advances Cannabinoid Delivery with Novel PwdRx Platform
TipRanks · 11/19 13:10
Avicanna announces preclinical data on PwdRx drug delivery platform
TipRanks · 11/19 12:45
AVICANNA ANNOUNCES PRE-CLINICAL DATA SUPPORTING ENHANCED ABSORPTION AND PATENT FILING FOR NOVEL ORAL DELIVERY PLATFORM
Reuters · 11/19 12:30
Weekly Report: what happened at AVCNF last week (1110-1114)?
Weekly Report · 11/17 09:44
Avicanna Reports Q3 2025 Growth and Strategic Advances
TipRanks · 11/14 23:43
AVICANNA REPORTS Q3 2025
Reuters · 11/14 22:30
Weekly Report: what happened at AVCNF last week (1103-1107)?
Weekly Report · 11/10 09:42
Weekly Report: what happened at AVCNF last week (1027-1031)?
Weekly Report · 11/03 09:42
Weekly Report: what happened at AVCNF last week (1020-1024)?
Weekly Report · 10/27 09:44
Weekly Report: what happened at AVCNF last week (1013-1017)?
Weekly Report · 10/20 09:43
Weekly Report: what happened at AVCNF last week (1006-1010)?
Weekly Report · 10/13 09:44
Weekly Report: what happened at AVCNF last week (0929-1003)?
Weekly Report · 10/06 09:42
Weekly Report: what happened at AVCNF last week (0922-0926)?
Weekly Report · 09/29 09:43
Weekly Report: what happened at AVCNF last week (0915-0919)?
Weekly Report · 09/22 09:42
Weekly Report: what happened at AVCNF last week (0908-0912)?
Weekly Report · 09/15 11:08
More
Webull provides a variety of real-time AVCNF stock news. You can receive the latest news about Avicanna through multiple platforms. This information may help you make smarter investment decisions.
About AVCNF
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.